linjc16/ctgov huggingface dataset:
CLIC1 in Patients Presenting PD

Study Overview
=================
Brief Summary
-----------------
In this study, mononuclear cells, particularly monocytes, were collected from the peripheral blood of elderly patients who underwent orthopedic hip surgery under spinal anesthesia. We then observe the accumulation of chloride intracellular channel 1 (CLIC1), particularly the characteristic accumulation morphology and its function. The purpose of this study is to compare whether there is a difference in the degree and form of cytoplasmic CLIC1 accumulation between the elderly group with postoperative delirium (PD) and the elderly group without postoperative delirium. We'll also confirm whether this is appropriate as a predictor of postoperative delirium. In addition, we will establish a control group for the non-elderly group to check the difference due to aging itself.

Official Title
-----------------
Accumulation of Chloride Intracellular Channel 1 (CLIC1) Protein in Circulating Monocyte in Elderly Patients Presenting Postoperative Delirium and Its Predictable Role of Postoperative Delirium

Conditions
-----------------
Hip Fractures, Hip Disease

Intervention / Treatment
-----------------
* Behavioral: Postoperative delirium
* Procedure: Hip surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Old group: Male or female patients aged 65 years or older who are scheduled to undergo surgery for an orthopedic hip fracture under spinal anesthesia Young group: Male or female patients between 20 and 50 years of age who are scheduled to undergo orthopedic hip joint surgery under spinal anesthesia Exclusion Criteria: Patients who are unconscious Patients who are unable to communicate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Old with postoperative delirium<br> | Behavioral: Postoperative delirium<br>* Postoperative delirium<br>Procedure: Hip surgery<br>* Orthopedic hip joint surgery under spinal anesthesia<br>|
| Old without postoperative delirium<br> | Procedure: Hip surgery<br>* Orthopedic hip joint surgery under spinal anesthesia<br>|
| Young<br> | Procedure: Hip surgery<br>* Orthopedic hip joint surgery under spinal anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression pattern of CLIC1 protein |  | Immediate after spinal anesthesia |
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice were performed.

Detailed Description
-----------------
A single center, observational, open-label, longitudinal, prospective study combined with retrospective data collection for 12 de novo renal transplant patients. Ten patients were prospectively followed for 12 months after receiving MyOra® (mycophenolate mofetil) and two patients were previously on MyOra® (mycophenolate mofetil), thus their data was retrospectively collected from their hospital records and all relevant workup tests results. Outcomes include occurrence of AEs and proportion of patients with normal graft function.

Official Title
-----------------
MyOra® (Mycophenolate Mofetil) Post-Authorization Safety Study for Prophylaxis in de Novo Renal Transplant Patients

Conditions
-----------------
Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant

Intervention / Treatment
-----------------
* Drug: Mycophenolate Mofetil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient received de novo renal transplant Patient treated with MyOra® according to the attending physician's judgment (either post-transplant or induction) Patient provided written informed consent Exclusion Criteria: Hypersensitivity to mycophenolate mofetil, mycophenolic acid (MPA) or any of the constituents of MyOra®
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence, severity and relationship of adverse events (AEs) to the Study medication | Rate of AEs, SAEs and laboratory tests abnormalities will be calculated | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with normal graft function | Graft status was estimated through the evaluation of kidney function in all patients enrolled in the study | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunosuppressant, MyOra, Mycophenolate Mofetil, End stage renal disease, De novo Renal transplant, Post authorization safety study, Cohort study
Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis

Study Overview
=================
Brief Summary
-----------------
Nocturnal calf cramps is a common complaint in patients with lumbar spinal stenosis. The purpose of this study is to evaluate the effect of botulinum toxin A injection into the gastrocnemius muscle in lumbar spinal stenosis patients receiving conservative therapy. We will compare pain score, insomnia severity, functional ability, patient satisfaction, and neurophysiological variables change using electrical stimulator between control (conservative management for spinal stenosis) and botox group (conservative management for spinal stenosis plus botox injection into the gastrocnemius muscle).

Conditions
-----------------
Spinal Stenosis With Nocturnal Calf Cramps

Intervention / Treatment
-----------------
* Drug: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed lumbar spinal stenosis with MRI finding nocturnal calf cramps symptoms at least once per week Exclusion Criteria: electrolyte disorder congenital muscle disease muscle cramps related medication (statins, diuretics, calcium channel blockers, anticonvulsants etc.) cognitive impairments

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control group<br> | Other: no intervention<br>* Patients in the control group will not receive any injection on the gastrocnemius muscle.<br>|
| Experimental: botox group<br> | Drug: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle<br>* ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score | A comparison of pain score between control (conservative management for spinal stenosis) and botox group (conservative management for spinal stenosis plus botox injection into the gastrocnemius muscle). | follow up 2 weeks (14 days) after injection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient satisfaction questionnaire using 0 to 4 scale | assessment of patient satisfaction using 0 to 4 scale (0; very dissatisfied, 1; dissatisfied, 2; fair, 3; satisfied, 4; very satisfied) | follow up 3 months after injection |
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Because of the demonstrated single agent activity and excellent tolerability in patients with refractory non-small cell lung cancer, ZD1839 may be of benefit in the first-line treatment of patients with advanced non-small cell lung cancer who have poor performance status. In this phase II trial, we will investigate the single agent activity of first-line ZD1839 in patients with advanced non-small cell lung cancer with poor performance status

Detailed Description
-----------------
Upon determination of eligibility, patients will be receive: ZD1839

Official Title
-----------------
Phase II Trial of Single Agent ZD1839 (Iressa) in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: ZD1839


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, you must meet the following criteria: Biopsy proven non-small cell lung cancer Recurrent non-small cell lung cancer after previous surgery or radiation Advanced disease (stage IIIb or IV) No previous chemotherapy or biological therapy Require significant assistance with activities of daily living Measurable disease Adequate bone marrow, liver and kidney function Give written informed consent Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Brain metastasis Meningeal metastasis Other uncontrolled malignancies Women pregnant or lactating No measurable disease outside previous radiation therapy field Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ZD1839|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall toxicity |  |  | 
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSCLC Lung Cancer, Non Small Cell Lung Cancer
Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach

Study Overview
=================
Brief Summary
-----------------
The peritoneum is the second most common site of recurrence in patients with colorectal cancer. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improve the prognosis of these patients and incorporates surgical removal of all visible disease followed by chemical destruction of microscopic disease through chemoperfusion. The most validated predictors of outcome are preoperative tumor burden measured in terms of the peritoneal carcinomatosis index (PCI) and completeness of cytoreduction (CC score). Diagnostic laparoscopy prior to resection is widely used in hepatopancreaticobiliary and colorectal cancer and has been shown to be effective in excluding unnecessary laparotomy associated with higher morbidity.

Official Title
-----------------
Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach

Conditions
-----------------
Colorectal Peritoneal Carcinomatosis

Intervention / Treatment
-----------------
* Other: Non interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Colorectal cancer with a resected minimal synchronous peritoneal carcinomatosis, or ovarian metastases, tumour rupture in the abdominal cavity. Patients received six months of systemic chemotherapy (currently the Folfox-4 regimen which could be modified if the standard is modified) Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Digestive peritoneal carcinomatosis staging<br>All patients underwent laparoscopic followed by laparotomic surgical staging. | Other: Non interventional<br>* Peroperative data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peritoneal carcinomatosis staging | To score the Collect detailed detailed Peritoneal Cancer Index (PCI) by laparoscopy following the laparotomy procedure in order to evaluate the accuracy and adequacy of laparoscopic surgical staging comparing to laparotomic approach. | during laparoscopy and during laparotomy (Day 1) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Digestive peritoneal carcinomatosis, laparoscopy, laparotomy, peritoneal cancer index (PCI), staging
Brain Imaging Study of Brain Plasticity in Chronic Stroke Patients

Study Overview
=================
Brief Summary
-----------------
In chronic stroke patients, brain network reorganization and recovery mechanism are investigated after stroke onset using functional MRI and diffusion tensor imaging analyses.

Official Title
-----------------
Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Study About Reorganization and Recovery Mechanism of Brain Neural Network for Chronic Stroke Patients

Conditions
-----------------
Chronic Stroke

Intervention / Treatment
-----------------
* Other: Chronic stroke


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 3 months post-stroke ischemic or hemorrhagic stroke a person who understands the experiment and has a willingness to participate and signs the agreement Exclusion Criteria: User of artificial heartbeat Patients with claustrophobia Patients with metal implants Patients who are contraindicated for other common MRI
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic stroke<br>More than 3 months post-stroke Ischemic or hemorrhagic stroke | Other: Chronic stroke<br>* MRI data acquisition and behavioral test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation coefficient between strength of connection and the Fugl-Meyer Assessment score | Strength of connection is obtained by calculating a correlation coefficient between time courses of both regions in fMRI data. | Through study completion, an average of 1 year | 
| Correlation coefficient between the FA value of a tract and the Fugl-Meyer Assessment score | FA value is obtained by assessing a diffusion anisotropy of a specific tract in DTI data. | Through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain connectivity, Magnetic resonance imaging, Brain plasticity, Recovery
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Study Overview
=================
Brief Summary
-----------------
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Conditions
-----------------
Hepatic Encephalopathy

Intervention / Treatment
-----------------
* Drug: Rifaximin SSD
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Diagnosis of liver cirrhosis with medically controlled ascites (>30 days) not requiring therapeutic paracentesis (could have had paracentesis in the past). Conn (West Haven Criteria) score of < 2. Mini-Mental State Examination (MMSE) score > 24 at screening. ≥ 18 and ≤ 85 years of age. Key Exclusion Criteria: Active COVID-19 that is unresolved History of SBP History of EVB or AKI-HRS within 6 months History of OHE episode (Conn score ≥ 2)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rifaximin SSD-40mg IR<br> | Drug: Rifaximin SSD<br>* Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo Twice Daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first event of overt hepatic encephalopathy requiring hospitalization |  | 72 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first Conn score ≥ 2 |  | 72 weeks | 
| Time to all-cause hospitalization |  | 72 weeks | 
| Time to first event of OHE that requires hospitalization, or all-cause death |  | 72 weeks |
Orthokeratology for Keratoconus

Study Overview
=================
Brief Summary
-----------------
To investigate a possible benefit of Orthokeratology contact lenses to improve uncorrected visual acuity of keratoconus patients

Official Title
-----------------
Orthokeratology Contact Lenses for Keratoconus

Conditions
-----------------
Orthokeratology, Keratoconus

Intervention / Treatment
-----------------
* Device: Orthokeratology contact lenses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Moderate Keratoconus No apical scars Exclusion Criteria: Advanced Keratoconus Apical scaring Contact lens intolerance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Keratoconus<br>One eye of Keratoconus patient | Device: Orthokeratology contact lenses<br>* Wearing Orthokeratology lens in one eye of a keratoconus patient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected Visual acuity |  | After 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of change in corneal video-topography |  | At one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keratoconus, Orthokeratology
Tab Block and Patient Controlled Analgesia in CS

Study Overview
=================
Brief Summary
-----------------
cesarean section rate become increasing nowadays

Detailed Description
-----------------
indication of cesarean section are different from case to case and the use of pain controlling agents is very important to relieve post operative pain

Official Title
-----------------
Effect of Tab Block and Patient Controlled Analgesia in Cesarean Section

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Drug: tab block
* Drug: PCA
* Drug: women who will not receive tab block or PCA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women coming for an elective CS Exclusion Criteria: women who has a n emergency CS or complicated normal deivery needs urgent CS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: giving tab block<br>giving patients tab block | Drug: tab block<br>* injection of tab block to women who are doing cs<br>Drug: women who will not receive tab block or PCA<br>* no tab block or PCA will be given<br>|
| Active Comparator: giving PCA<br>Giving PCA to patients | Drug: PCA<br>* giving women PCA<br>Drug: women who will not receive tab block or PCA<br>* no tab block or PCA will be given<br>|
| No Intervention: Patients who will not receive PCA or tab block<br>No tab block or PCA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of women who will feel less pain post CS | the degree of pain that will be felt post CS | 2 days |